U.S. markets closed

Novacyt S.A. (NVYTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
4.50000.0000 (0.00%)
At close: 9:33AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.5000
Open4.5000
BidN/A x N/A
AskN/A x N/A
Day's Range4.5000 - 4.5000
52 Week Range4.5000 - 16.0000
Volume75
Avg. Volume157
Market Cap320.279M
Beta (5Y Monthly)-3.61
PE Ratio (TTM)1.67
EPS (TTM)2.6970
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Novacyt S.A.: David Allmond Announced as CEO Following Decision by Graham Mullis to Retire

    PARIS & CAMBERLEY, England, July 29, 2021--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) ("Novacyt", the "Company" or the "Group"), a leading international specialist in clinical diagnostics, announces the appointment of David Allmond as CEO and a member of the Board of Directors effective from 18 October 2021. At that time Graham Mullis, having informed the Board that he wishes to retire after 13 years with the expanded Group, will stand down as CEO and board member.

  • Business Wire

    Novacyt S.A. ("Novacyt", the "Company" or the "Group"): Expansion of PathFlow® COVID-19 Lateral Flow Test Portfolio

    PARIS & CAMBERLEY, England, June 29, 2021--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is to launch two PathFlow® COVID-19 antigen lateral flow tests (LFTs) to strengthen the Company’s COVID-19 portfolio and to pursue significant new market opportunities, especially in point-of-care (POC) settings. The Company will initially target private market opportunities for these LFTs via its existing distribution network.

  • Business Wire

    Novacyt S.A.: Full Year 2020 Results and Update on Growth Strategy

    PARIS & CAMBERLEY, England, Jun 22, 2021--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) ("Novacyt", the "Company" or the "Group"), an international specialist in clinical diagnostics, announces its audited results for the year ended 31 December 2020 and provides an update on its growth strategy.